More Related Content
Similar to LED Medical Diagnostics - Investor Presentation April 2014
Similar to LED Medical Diagnostics - Investor Presentation April 2014 (20)
More from Company Spotlight
More from Company Spotlight (20)
LED Medical Diagnostics - Investor Presentation April 2014
- 2. Forward Looking Statements
Certain information contained in this presentation of LED Medical Diagnostics Inc. (the
“Company”) constitutes “forward-looking statements“ within the meaning of securities laws.
Actual events or results could differ materially from expectations and projections. Forward-
looking statements include, among other things, statements relating to expected growth,
potential market size and market share, expected revenues and margins, introduction of new
products, results of operations, performance, business prospects and realization of cost savings.
Forward-looking statements are based on the opinions and estimates of management at the date
the statements are made, and are subject to a variety of risks and uncertainties and other factors
that could cause actual events or results to differ materially from those projected in the forward-
looking statements. These risks and other factors include, among other things, availability of
funds, general economic, market and business conditions, competitor risks, distributor risks,
intellectual property risks, regulatory approvals and other risks described in the Company’s
Annual Information Form available at www.sedar.com. Except as required by law, the Company
disclaims any intention or obligation to update or revise the forward-looking information,
whether as a result of new information, future events or otherwise. The forward-looking
statements in this document are provided for the limited purpose of enabling potential investors
to evaluate an investment in the securities of the Company. Readers are cautioned that such
statements may not be appropriate, and should not be used, for other purposes.
Nothing in this presentation should be construed as either an offer to sell or a solicitation of an
offer to buy or sell securities in any jurisdiction.
Copyright © 2014 LED Medical Diagnostics Inc. | 2
- 3. Who We Are
• Genesis as the developer of the world’s
leading adjunctive device for oral mucosal
disease (including cancer)
• Becoming a comprehensive digital imaging
technology supplier
• Positioned to become the North American
leader in the dental imaging category
Copyright © 2014 LED Medical Diagnostics Inc. | 3
- 4. Proven Executive Management
• Dr. David Gane, DDS
CEO
– High-achieving corporate strategist in
dental imaging industry
– Various roles as CEO, President, and VP
– Has demonstrated abilities to introduce
new products to achieve ambitious
revenue and profitability goals while
creating high-functioning and driven
teams.
– www.linkedin.com/in/dgane
Copyright © 2014 LED Medical Diagnostics Inc. | 4
- 5. Proven Executive Management
• Lamar Roberts
President, LED Imaging
– Senior sales and marketing executive
– Demonstrated success in leading growth in
Dental Technology companies
– Demonstrated ability to navigate companies
from their early stages to becoming an
industry leader.
– Proven leadership in public companies.
Effective in leading mergers, acquisitions,
integrations, sales, marketing, product
management, operations and admin
Copyright © 2014 LED Medical Diagnostics Inc. | 5
- 6. Where We Came From
• Carestream Dental
• Revenue $2.5B
• Dental revenues: $500MM
• 7000 employees who serve customers in 150
countries
• Dental Division: 1200 employees
• Products in 90 percent of hospitals and dental
practices worldwide
Copyright © 2014 LED Medical Diagnostics Inc. | 6
- 7. Our Future
We are building a high-value dental imaging
company by growing our VELscope® technology
foundation while adding complementary
diagnostic imaging products that leverage our
established brand.
Copyright © 2014 LED Medical Diagnostics Inc. | 7
- 8. VELscope® Vx : How It Works
An Easy-to-Use Handheld Device
Copyright © 2014 LED Medical Diagnostics Inc. | 8
- 9. The VELscope® Vx Scan
Early Detection of Occult Lesions
View with the Naked Eye View Using VELscope™ VX
(biopsy confirmed oral cancer)
Copyright © 2014 LED Medical Diagnostics Inc. | 9
- 10. Dental Imaging Opportunity
• Imaging fundamental to Diagnosis &
Tx Planning
• “Explosive Growth in Dental Implant
& CAD CAM Ensures Market
Recovery and Fuels Esthetic Sales”
• Imaging moving from realm of pure
diagnosis to guided imaging
treatments
• The global market for dental
imaging systems is predicted to
reach over $2.3B by 2022
Copyright © 2014 LED Medical Diagnostics Inc. | 10
- 11. New LED Imaging Division
• We have recognized an unmet demand for new types
of digital imaging technology in the dental market.
• Driven by:
– Demand for cosmetic dental procedures such as
orthodontics, composites, veneers and crowns
– Shift from film-based systems to faster, more efficient and
higher quality digital imaging solutions.
• Founded LED Imaging Division in April 2014
Copyright © 2014 LED Medical Diagnostics Inc. | 11
- 13. New Partnership with Ray Co.
• Signed with Ray Co.- Samsung
subsidiary in April 2014
• “Best-of-class” multi-function
digital extraoral imaging
system – “RAYSCAN α”
• High demand – two systems
already in-situ (six figure price
per system)
Copyright © 2014 LED Medical Diagnostics Inc. | 13
- 14. New Partnership with BC Cancer Agency / Genome BC
• LED Medical /BC Cancer Agency /Genome BC:
create/commercialize groundbreaking Oral Cancer
Risk‐Assessment Test
• Technology to build upon $10MM of National Institute of Health and TFRI
Research Funding
• Test is a first of its kind for oral cancer based on a quantifiable genetic
phenomenon known as “Loss of Heterozygosity,” or “LOH.”
• Measures specific genetic changes shown to predict aggressive tumour
growth - potential to lower oral cancer morbidity and mortality rates.
• Determines if remove immediately or something you need to be
concerned about and just watch,
• Extensive market opportunity - the test also could be used by family
doctors, hygienists, or ear, nose, and throat specialists
Copyright © 2014 LED Medical Diagnostics Inc. | 14
- 15. 2014 Strategic Plan
• New executive management team with current CEO
transitioning to lead future product development
• Expansion of sales, marketing & operations teams in the US
in FY14 – Atlanta office established
• Optimization of current dealer relationships and expansion
of VELscope® sale channels via non-exclusive dealers across
North America
• Major imaging product diversification strategy underway
• Significant revenue growth with expectation that majority of
new revenues/margin anticipated from new digital imaging
products during FY14
• Increased investment in R&D new product / IP in FY14
Copyright © 2014 LED Medical Diagnostics Inc. | 15
- 16. Six Month Milestones
• APR 3, 2014: Distribution partnership with Samsung subsidiary Ray Co.
• APR 3, 2014: Founding of LED Imaging Division
• JAN 21, 2014: Sign Patterson Dental - 85 branch offices across USA and over 1,500 sales reps
• JAN 14, 2014 : Agreement with BC Cancer Agency/Genome British Columbia
(Genome BC) to create and commercialize a progression‐risk assessment test for oral cancer.
The test is based on a quantifiable genetic phenomenon known as “Loss of Heterozygosity” - the
first of its kind for oral cancer
• DEC 10, 2013: Sign Benco Dental - More than 35,000 customers across the country and
maintains an excellent reputation in the dental industry.
• DEC 3, 2013: Sign Burkhart Dental - one of the most respected dental distributors in the
United States for over 125 years
• OCT 29, 2013: Sign Sinclair Dental - fastest growing, full-service dental supply companies in
Canada. Sinclair has an experienced team of over 500 individuals operating within 10 regional
offices.
Copyright © 2014 LED Medical Diagnostics Inc. | 16
We are executing quickly…
- 17. Capital Structure*
• Founded 2003 - $50MM in non-dilutive capital via government
grants, mainly the NIH/BCCS
• Paid in private capital: $30MM
• Common Shares outstanding: 73.8MM
• Option outstanding – 6.4MM (price range from $0.30 to $0.54)
• DSUs outstanding – 950K at $0.25
• Warrants outstanding - 34MM
– 17,845,000 @ 0.20 (Exp. June 14, 2015)
– 30,800 @ 0.30 (Exp. June 21, 2014)
– 16,109,887 @ 0.50 (Exp. October 24, 2015)
– Potential proceeds of $11.6MM
• Fully Diluted: 115MM
* All numbers approximate
Copyright © 2014 LED Medical Diagnostics Inc. | 17
Editor's Notes
- MH – add conclusion slide
- MH – add conclusion slide
